A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
Summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD. The first intervention planned to be evaluated is GHZ339. Participants will be randomly assigned to one of the study arms.
Eligibility
- Age range
- 18–100 years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria of the master protocol: * Able and willing to sign the informed consent (IC) * Patients with a diagnosis of AD and onset of disease for at least 1 year * Moderate to severe AD Key Exclusion Criteria of the master protocol: * Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol) * Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG * Participant with any other active inflammatory skin disease * Participants with any chronic…
Interventions
- DrugGHZ339
GHZ339 administered at dose A, B, C and D
- DrugPlacebo
Matching placebo
Locations (99)
- Novartis Investigative SiteBirmingham, Alabama
- Novartis Investigative SiteBirmingham, Alabama
- Novartis Investigative SiteFort Smith, Arkansas
- Novartis Investigative SiteFountain Valley, California
- Novartis Investigative SiteLos Angeles, California
- Novartis Investigative SiteSacramento, California